Cue Biopharma's CUE-221 Hits Phase II Goals, Shows Durable CSU ResponseMarketBeat · Sep 28, 2026
Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU ResponseDefense World · Sep 28, 2026
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOASeeking Alpha · Sep 21, 2026
Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria TranscriptSeeking Alpha · Sep 21, 2026
What's Going on With Cue Biopharma Stock on Monday?Benzinga · Sep 21, 2026
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous UrticariaGlobeNewsWire · Sep 20, 2026Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$1.69 | -$24.14 | Miss |
| May 14, 2026 | -$3.30 | -$1.08 | Beat |
| Mar 16, 2026 | -$2.70 | $0.30 | Beat |
| Nov 12, 2025 | -$2.80 | -$2.10 | Beat |
| Aug 12, 2025 | -$3.90 | -$2.70 | Beat |
| May 12, 2025 | -$4.20 | -$5.11 | Miss |